OLMA News and Press, Olema Pharmaceuticals Inc. From 05/09/23

2023-05-09 18:04:59 ET Olema Pharmaceuticals press release ( NASDAQ: OLMA ): Q1 GAAP EPS of -$0.70 misses by $0.04 . Cash, cash equivalents and marketable securities as of March 31, 2023, were $186.0 million. Olema anticipates that this balance will be suffic...

Initiation of first pivotal Phase 3 monotherapy clinical trial of OP-1250 in second- and third-line metastatic breast cancer planned for the second half of 2023 Interim Phase 2 clinical results of OP-1250 in combination with palbociclib to be presented at the 2023 ESMO Breast Cancer Annua...

SAN FRANCISCO, May 08, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s ...

2023-04-21 17:40:45 ET Gainers: Starbucks Corporation ( SBUX ) +6% . Caesars Entertainment ( CZR ) +5% . Gritstone bio ( GRTS ) +4% . JFrog ( FROG ) +3% . UP Fintech Holding  ( TIGR ) +3% . Losers: Presto Automation ...

SAN FRANCISCO, April 13, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s...

2023-03-10 11:19:47 ET Olema Oncology ( NASDAQ: OLMA ) will let go of ~25% of its employees across research, early development, and general and administrative functions as part of a restructuring. The move is being done so the company can focus on late-stage development of...

2023-03-09 17:25:45 ET Olema Pharmaceuticals press release ( NASDAQ: OLMA ): Q4 GAAP EPS of -$0.65 in-line. Cash, cash equivalents and marketable securities as of December 31, 2022, were $204.4 million. Olema anticipates that this balance will be sufficient to fu...

Significant progress made advancing lead program, OP-1250, with more than 170 patients treated to date Initiating first pivotal Phase 3 monotherapy clinical trial of OP-1250 in second- and third-line metastatic breast cancer in the second half of 2023 Corporate restructuri...

SAN FRANCISCO, March 02, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s...

SAN FRANCISCO, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s ...